Hidden Trends in 90 Years of Harvard Business Review

In this paper, we demonstrate and discuss results of our mining the abstracts of the publications in Harvard Business Review between 1922 and 2012. Techniques for computing n-grams, collocations, basic sentiment analysis, and named-entity recognition were employed to uncover trends hidden in the abstracts. We present findings about international relationships, sentiment in HBR's abstracts, important international companies, influential technological inventions, renown researchers in management theories, US presidents via chronological analyses.Comment: 6 pages, 14 figures, Proceedings of 2012 International Conference on Technologies and Applications of Artificial Intelligenc

Solitons in Open N=2 String Theory

The open N=2 string theory is defined on the four-dimensional space-time with the split signature (+,+,-,-). The string field theory action of the open N=2 string theory is described by the four-dimensional Wess-Zumino-Witten (WZW_4) model. Equation of motion of the WZW_4 model is the Yang equation which is equivalent to the anti-self-dual Yang-Mills equation. In this paper, we study soliton-type classical solutions of the WZW_4 model in the split signature by calculating the action density of the WZW_4 model. We find that the action density of the one-soliton solutions is localized on a three-dimensional hyperplane. This shows that there would be codimension-one-solitonic objects, or equivalently, some kind of three-branes in the open N=2 string theory. We also prove that in the asymptotic region of the space-time, the action density of the n-soliton solutions is a ``nonlinear superposition'' of n one-solitons. This suggests the existence of intersecting n three-branes in the N=2 strings. Finally we make a reduction to a (1+2)-dimensional real space-time to calculate energy densities of the soliton solutions. We can successfully evaluate the energy distribution for the two-soliton solutions and find that there is no singularity in the interacting region. This implies the existence of smooth intersecting codimension-one branes in the whole region. Soliton solutions in the Euclidean signature are also discussed.Comment: 54 pages, 2 figures; v2: minor changes; v3: minor changes; v4: a reference added, typos corrected, published versio

Soliton solutions of noncommutative anti-self-dual Yang-Mills equations

We present exact soliton solutions of anti-self-dual Yang-Mills equations for G = GL(N) on noncommutative Euclidean spaces in four-dimension by using the Darboux transformations. Generated solutions are represented by quasideterminants of Wronski matrices in compact forms. We give special one-soliton solutions for G = GL(2) whose energy density can be real-valued. We find that the soliton solutions are the same as the commutative ones and can be interpreted as one-domain walls in four-dimension. Scattering processes of the multi-soliton solutions are also discussed

MCRS2 represses the transactivation activities of Nrf1

<p>Abstract</p> <p>Background</p> <p>Nrf1 [p45 nuclear factor-erythroid 2 (p45 NF-E2)-related factor 1], a member of the CNC-bZIP (CNC basic region leucine zipper) family, is known to be a transcriptional activator by dimerization with distinct partners, such as Maf, FosB, c-Jun, JunD, etc. The transcriptional roles of CNC-bZIP family are demonstrated to be involved in globin gene expression as well as the antioxidant response. For example, CNC-bZIP factors can regulate the expression of detoxification proteins through AREs, such as expression of human gamma-glutamylcysteine synthetases (GCS), glutathione S-transferases (GST), UDP-glucuronosyl transferase (UDP-GT), NADP (H) quinone oxidoreductase (NQOs), etc. To further explore other factor(s) in cells related to the function of Nrf1, we performed a yeast two-hybrid screening assay to identify any Nrf1-interacting proteins. In this study, we isolated a cDNA encoding residues 126–475 of MCRS2 from the HeLa cell cDNA library. Some functions of MCRS1 and its splice variant-MSP58 and MCRS2 have been previously identified, such as transforming, nucleolar sequestration, ribosomal gene regulation, telomerase inhibition activities, etc. Here, we demonstrated MCRS2 can function as a repressor on the Nrf1-mediated transactivation using both in vitro and in vivo systems.</p> <p>Results</p> <p>To find other proteins interacting with the CNC bZIP domain of Nrf1, the CNC-bZIP region of Nrf1 was used as a bait in a yeast two-hybrid screening assay. MCRS2, a splicing variant of p78/MCRS1, was isolated as the Nrf1-interacting partner from the screenings. The interaction between Nrf1 and MCRS2 was confirmed <it>in vitro </it>by GST pull-down assays and <it>in vivo </it>by co-immunoprecipitation. Further, the Nrf1-MCRS2 interaction domains were mapped to the residues 354–447 of Nrf1 as well as the residues 314–475 of MCRS2 respectively, by yeast two-hybrid and GST pull-down assays. By immunofluorescence, MCRS2-FLAG was shown to colocalize with HA-Nrf1 in the nucleus and didn't result in the redistribution of Nrf1. This suggested the existence of Nrf1-MCRS2 complex in vivo. To further confirm the biological function, a reporter driven by CNC-bZIP protein binding sites was also shown to be repressed by MCRS2 in a transient transfection assay. An artificial reporter gene activated by LexA-Nrf1 was also specifically repressed by MCRS2.</p> <p>Conclusion</p> <p>From the results, we showed MCRS2, a new Nrf1-interacting protein, has a repression effect on Nrf1-mediated transcriptional activation. This was the first ever identified repressor protein related to Nrf1 transactivation.</p

Comparison of a Chinese Herbal Medicine (CCH1) and Lactulose as First-Line Treatment of Constipation in Long-Term Care: A Randomized, Double-Blind, Double-Dummy, and Placebo-Controlled Trial

Many institutionalized patients and their healthcare providers are dissatisfied with current laxative therapy. This study compared therapeutic efficacy, safety, and laxative cost of an herbal formula (CCH1) and lactulose for long stay patients with constipation. In this double-blind, double-dummy, and placebo-controlled trial, we randomized 93 residents with chronic constipation from two long-term care facilities in Taiwan to receive either CCH1 with lactulose placebo or CCH1 placebo with lactulose for 8 weeks, then followed up for 4 weeks without study medication. Both treatments were effective and well tolerated for patients, but CCH1 produced more spontaneous bowel movements, less rectal treatments, less amount of rescue laxative, and lower laxative cost than lactulose during treatment. No significant differences were found in stool consistency, stool amount, global assessment, and safety concerns. In conclusion, our results suggest that CCH1 may have better efficacy and could be used as an alternative option to lactulose in the treatment of constipation in long-term care